Health Technology · Pharmaceuticals: Generic · NSE: ZIMLAB · data 2026-10-09
Zim Laboratories Ltd.
Health check: Weak (3.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹150.47
Market cap
₹755 cr
P/E
182.4
P/B
—
ROE
2.1%
ROCE
1.7%
Debt / equity
0.43
Dividend yield
0.00%
1-year return
113.4%
52-week high
₹153.94
52-week low
₹59.31
Operating margin
1.9%
Growth
| Revenue (last 12 months) | ₹397 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | -2.2% |
| Profit growth, 3 years (yearly) | -37.9% |
Chart patterns
- Double bottom — breakout (key level ₹130.4)
- Ascending triangle — breakout (key level ₹144.49)
Similar companies
Hexagon Nutrition Limited (HEXAGON) · Anuh Pharma Limited (ANUHPHR) · MIC Electronics Limited (MICEL) · Amanta Healthcare Limited (AMANTA) · Wanbury Limited (WANBURY)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ZIMLAB in NSE Scanner →